[A25-122] Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V

Last updated 10.12.2025

Project no.:
A25-122

Commission:
Commission awarded on 19.09.2025 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission work started

Department/Division:
Drug Assessment

Topic:
Cancer

Project no.	Title	Status
A25-119	Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V	Commission work started
A25-118	Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V	Commission work started
A24-131	Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-129	Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-128	Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V	Commission completed
A24-127	Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V	Commission completed
A24-126	Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V	Commission completed
A24-130	Tislelizumab (oesophageal carcinoma, advanced, second line) – Benefit assessment according to §35a Social Code Book V	Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.